Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 13/20 | 0.68 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.58 |
| ▸ | HTR2C | P28335 | 3/20 | 0.52 |
| ▸ | MAOB | P27338 | 3/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1775734 | 0.82 | HTR6 (0.46) | HTR6HTR2C | |
| SCHEMBL7533961 | 0.78 | HTR6 (0.80) | HTR6HRH4MAOB | |
| SCHEMBL1776127 | 0.78 | HTR6 (0.71) | HTR6HTR2C | |
| Hydrochloric Acid SCHEMBL1776337 | 0.77 | HTR6 (0.69) | HTR6HTR2C | |
| SCHEMBL6638475 | 0.77 | HTR6 (0.51) | HTR6HRH4MAOB | |
| Water SCHEMBL6643706 | 0.76 | HTR6 (0.55) | HTR6HTR2C | |
| SCHEMBL12601683 | 0.74 | HTR6 (0.50) | HTR6 | |
| SCHEMBL1776812 | 0.73 | HTR6 (1.00) | HTR6 | |
| SCHEMBL408644 | 0.73 | KLKB1 (0.63) | HTR6 | |
| SCHEMBL26534468 | 0.73 | HTR6 (0.52) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1078928-B1 | Pyridine derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2004-05-12 | — | — | EP | disclosed |
| US-6486171-B2 | USEFUL IN THE TREATMENT OF SOME CENTRAL NERVOUS SYSTEM DISORDERS INCLUDING AS AN ANTIDEPRESSANT; 4-(1-(2-NAPHTHYL)ETHYL)-4- PIPERIDINYL)THIENO(3,2-C)PYRIDINE, FOR EXAMPLE | LES LABORATOIRES SERVIER (FR) | 2002-11-26 | — | — | US | disclosed |
| US-20020161228-A1 | Piperidine compounds | ADIR ET COMPAGNIE | 2002-10-31 | — | — | US | disclosed |
| US-6399616-B1 | 4-(4-(2-(5-(1,2,4-TRIAZOL-1-YLMETHYL)-1H-INDOL-3-YL)ETHYL)-1 -PIPERAZINYL)FURO(3,2-C)PYRIDINE; COMBINED SEROTONIN REUPTAKE INHIBITOR AND PARTIAL AGONIST OF 5-HT RECEPTORS; REDUCED LATENCY; DEPRESSION | LES LABORATOIRES SERVIER (FR) | 2002-06-04 | — | — | US | disclosed |
| EP-1078928-A1 | Pyridine derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161228-A1 | Piperidine compounds | OTC, NPPA, AQP4 | HTR6 1926/4885HRH4 1040/4885HTR2C 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.